Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the EDGAR system. As a Nasdaq‑listed biopharmaceutical issuer incorporated in England and Wales, Kiniksa uses these filings to report financial results, clinical and regulatory milestones, and other material corporate information.
Form 8‑K filings for KNSA document events such as quarterly financial results, investor presentations, and other significant updates. For example, Kiniksa has used Form 8‑K to furnish press releases announcing results for quarters ended June 30 and September 30, 2025, and to file an investor presentation used in meetings with investors and analysts. These filings also confirm that Kiniksa’s Class A ordinary shares trade on The Nasdaq Global Select Market under the symbol KNSA.
Investors can also review Kiniksa’s periodic reports, such as Forms 10‑K and 10‑Q, which typically contain detailed information on ARCALYST net product revenue, operating expenses, cash, cash equivalents, and short‑term investments, as well as risk factors and discussion of the company’s IL‑1‑focused portfolio. For a biopharmaceutical company like Kiniksa, these reports are central to understanding how ARCALYST commercialization and the development of KPL‑387 and KPL‑1161 affect overall financial performance and strategy.
On Stock Titan, AI‑powered summaries help interpret lengthy KNSA filings by highlighting key points in plain language, such as changes in revenue guidance, updates on the Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, or disclosures about Orphan Drug Designation. Users can quickly locate references to IL‑1R1‑targeted programs, cardiovascular indications, and other topics without reading every page.
In addition, the filings page offers streamlined access to other important documents, including any proxy statements and beneficial ownership or insider‑related filings when available. Together, these SEC documents and AI‑generated insights give readers a structured view of Kiniksa’s regulatory history, financial reporting, and pipeline‑related disclosures.
Kiniksa Pharmaceuticals International, plc Chief Strategy Officer Eben Tessari reported several equity compensation transactions. On April 1, 2026, Tessari received a grant of 33,200 share options for Class A Ordinary Shares at an exercise price of $48.13 per share, expiring on March 31, 2036. The option vests 25% on April 1, 2027, then in 36 monthly installments.
On the same date, Tessari was granted 8,300 Restricted Share Units (RSUs) and 16,600 Performance Share Units (PSUs), each tied to Class A Ordinary Shares. The RSUs vest over four years, with 25% vesting on April 1, 2026 and annually thereafter. The PSUs convert into up to 200% of one share each, based on performance, no later than January 30, 2028.
Also on April 1, 2026, previously granted RSUs vested and were settled into 5,975 Class A Ordinary Shares. Of these, 1,756 shares were withheld at $48.13 per share to satisfy tax obligations, a non‑market disposition, leaving Tessari with 21,250 Class A Ordinary Shares held directly after the transactions. Earlier, on January 15, 2026, Tessari acquired 365 shares at $24.16 per share through the company’s 2018 Employee Share Purchase Plan, an acquisition exempt under Rule 16b‑3(e).
Kiniksa Pharmaceuticals International, plc reported that Chief Financial Officer Mark Ragosa received new equity awards and saw prior awards vest into shares. On April 1, 2026, he was granted 31,150 share options with an exercise price of $48.13 per share, vesting over four years, and expiring in 2036.
He also received 7,800 Restricted Share Units and 15,600 Performance Share Units, each tied to one Class A Ordinary Share, with PSUs payable based on performance and eligible to convert into up to 200% of one share by January 30, 2029. Existing RSUs vested into 5,187 Class A Ordinary Shares, of which 2,510 shares were withheld at $48.13 per share to cover tax obligations, leaving Ragosa holding 14,763 Class A Ordinary Shares directly.
Kiniksa Pharmaceuticals International, plc director and CEO Sanj K. Patel reported equity compensation grants and related share movements. On April 1, 2026, he received a grant of 120,150 share options with an exercise price of $48.13 per share, expiring on March 31, 2036, which vest over time starting April 1, 2026.
He was also granted 30,050 Restricted Share Units (RSUs) vesting over four years from April 1, 2026, and 60,100 Performance Share Units (PSUs), each representing a contingent right to receive Class A Ordinary Shares based on performance and vesting no later than January 30, 2029 at up to 200% of target.
In addition, previously granted RSUs totaling 21,327 units converted into the same number of Class A Ordinary Shares held indirectly through The Patel Family Irrevocable Trust of 2025. Of these, 10,313 shares were disposed of to satisfy tax obligations at $48.13 per share, leaving the trust with 71,014 shares. Separate trusts indirectly hold 109,795 and 51,794 Class A shares, reflecting substantial ongoing ownership.
Kiniksa Pharmaceuticals International, plc reported multiple equity awards and related exercises for its Chief Medical Officer, John F. Paolini, on April 1, 2026. He received a share option for 26,750 Class A Ordinary Shares at an exercise price of $48.13 per share, expiring on March 31, 2036, that vests over time starting April 1, 2026.
He was also granted 6,700 Restricted Share Units and 13,400 Performance Share Units, each linked to Class A Ordinary Shares and subject to four-year time-based or performance-based vesting, with PSUs eligible to convert into up to 200% of one share each by January 30, 2029. In addition, Paolini exercised previously granted RSUs for 5,831 Class A Ordinary Shares, with 2,821 shares withheld at $48.13 per share to cover tax obligations.
Following these transactions, Paolini directly holds 64,334 Class A Ordinary Shares, reflecting routine compensation-related equity activity rather than open-market buying or selling.
Kiniksa Pharmaceuticals International, plc chief operating officer Ross Moat reported multiple equity awards and related share activity. On April 1, 2026, he received a share option grant for 36,950 shares with an exercise price of $48.13 per share, expiring on March 31, 2036.
He was also granted 9,250 Restricted Share Units and 18,500 Performance Share Units, each tied to Class A Ordinary Shares and subject to multi‑year vesting and, for PSUs, performance criteria through January 30, 2029. On the same date, he exercised previously granted RSUs into 5,808 Class A Ordinary Shares, with 1,706 shares withheld at $48.13 per share to cover tax obligations.
Following these transactions, Moat held 14,396 Class A Ordinary Shares directly. Earlier, on January 15, 2026, he acquired 879 Class A Ordinary Shares at $24.16 per share under the company’s 2018 Employee Share Purchase Plan, an acquisition noted as exempt under Rule 16b‑3(e).
Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna reported multiple equity compensation transactions. On April 1, 2026, he received a share option for 14,600 shares at an exercise price of $48.13, vesting over four years starting April 1, 2026.
He was also granted 3,650 Restricted Share Units and 7,300 Performance Share Units, each tied to Class A Ordinary Shares and subject to multi‑year time- and performance-based vesting. The filing shows RSU exercises converting into 7,564 Class A Ordinary Shares, with 3,205 shares withheld at $48.13 to cover tax obligations.
Following these transactions, Megna directly holds 31,777 Class A Ordinary Shares. Footnotes describe prior participation in the 2018 Employee Share Purchase Plan and detail vesting schedules for the options, RSUs, and PSUs, including potential PSU settlement by January 30, 2029 based on performance.
The Vanguard Group filed Amendment No. 7 to a Schedule 13G/A reporting that it beneficially owns 0 shares of Kiniksa Pharmaceuticals International Plc common stock, representing 0% of the class. The filing states an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report separately. The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Kiniksa Pharmaceuticals International, plc Chief Financial Officer Mark Ragosa exercised stock options and sold shares in a planned transaction. On March 9, 2026, he exercised options covering 36,722 Class A Ordinary Shares at exercise prices between $17.76 and $26.74 per share. The same day, he sold 17,981 shares at $45.58 per share and 18,741 shares at $46.24 per share in open‑market transactions. These sales, totaling 36,722 shares, were carried out under a pre‑arranged Rule 10b5‑1 trading plan executed on August 14, 2025. Following the transactions, Ragosa directly owned 12,086 Class A Ordinary Shares.
Kiniksa Pharmaceuticals Ltd. submitted a Rule 144 notice reporting proposed sale of Class A ordinary shares related to an Employee Stock Option Exercise dated 03/09/2026. The filing lists 36,722 shares in the securities-to-be-sold row and discloses prior sales by Mark Ragosa of 12,000 shares on 01/08/2026 and 17,845 shares on 02/09/2026, with corresponding proceeds of $502,628.00 and $772,311.00.
FMR LLC reports beneficial ownership in Kiniksa Pharmaceuticals International plc Class A common stock. The filing shows FMR LLC (and Abigail P. Johnson in related capacity) beneficially owns 4,854,354.23 shares, equal to 10.6% of the class as reported with a 02/27/2026 reference. The cover lists sole voting power of 4,852,623 shares and sole dispositive power of 4,854,354.23 shares. The schedule includes an Exhibit 99 13d-1(k)(1) agreement and signatures by an authorized representative on 03/05/2026.